Browse by author
Lookup NU author(s): Dr Vinod Hegade,
Dr Richard Speight,
Professor David Jones
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
Recent developments in understanding the role of bile acids (BAs) as signalling molecules in human metabolism and inflammation have opened new avenues in the field of hepatology research. BAs are no longer considered as simple molecules helping in fat digestion but as agents with real therapeutic value in treating complex autoimmune and metabolic liver diseases. BAs and their receptors such as farnesoid X receptor, transmembrane G protein-coupled receptor 5 and peroxisome proliferator-activated receptor have been identified as novel targets for drug development. Some of these novel pharmaceuticals are already in clinical evaluation with the most advanced drugs having reached phase III trials. Chronic liver diseases such as primary biliary cholangitis, primary sclerosing cholangitis and nonalcoholic fatty liver disease, for which there is no or limited pharmacotherapy, are most likely to gain from these developments. In this review we discuss recent and the most relevant basic and clinical research findings related to BAs and their implications for novel therapy for chronic liver diseases.
Author(s): Hegade VS, Speight RA, Etherington RE, Jones DEJ
Publication type: Review
Publication status: Published
Journal: Therapeutic advances in gastroentology
Print publication date: 01/05/2016
Acceptance date: 01/01/1900
ISSN (print): 1756-283X
ISSN (electronic): 1756-2848
Publisher: SAGE PUBLICATIONS LTD